PRNewswire

February 2, 2026

Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites

read more →

PRNewswire

January 21, 2026

Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad

read more →

Clinical Leader

April 3, 2026

With A Clear Focus And Promising Asset, Crystalys Is Skipping Phase 2 Trials For Gout

read more →

Pharmaphorum

March 30, 2026

Changing Faces: Board of Directors and Advisory Boards, February 2026

read more →